{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:48:00Z","timestamp":1791406080471,"version":"4.3.3"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.beem.2025.102055","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:40:49Z","timestamp":1759995649000},"page":"102055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["New potential treatment options for syndrome of inappropriate antidiuresis"],"prefix":"10.1016","volume":"40","author":[{"given":"Sophie","family":"Monnerat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2025.102055_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/0002-9343(67)90096-4","article-title":"The syndrome of inappropriate secretion of antidiuretic hormone","volume":"42","author":"Bartter","year":"1967","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2025.102055_bib2","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2025.102055_bib3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cen.13388","article-title":"Mortality rates are lower in SIAD, than in hypervolaemic or hypovolaemic hyponatraemia: results of a prospective observational study","volume":"87","author":"Cuesta","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2025.102055_bib4","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnad010","article-title":"Syndrome of inappropriate antidiuresis: from pathophysiology to management","author":"Warren","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2025.102055_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0002-9343(57)90224-3","article-title":"A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone","volume":"23","author":"Schwartz","year":"1957","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2025.102055_bib6","first-page":"S36","article-title":"Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis","volume":"119","author":"Robertson","year":"2006"},{"key":"10.1016\/j.beem.2025.102055_bib7","unstructured":"Sterns RH, General Principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema), Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http:\/\/www.uptodate.com. Accessed [2023-Feb-21]."},{"key":"10.1016\/j.beem.2025.102055_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beem.2016.02.009","article-title":"The syndrome of inappropriate antidiuresis (SIAD)","volume":"30","author":"Cuesta","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.102055_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.797039","article-title":"The role of vasopressin V2 receptor in Drug-Induced hyponatremia","volume":"12","author":"Kim","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.beem.2025.102055_bib10","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1056\/NEJMoa042743","article-title":"Nephrogenic syndrome of inappropriate antidiuresis","volume":"352","author":"Feldman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2025.102055_bib11","first-page":"1070","article-title":"Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis","volume":"88","author":"Erd\u00e9lyi","year":"2015"},{"key":"10.1016\/j.beem.2025.102055_bib12","article-title":"Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia","author":"Baek","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.beem.2025.102055_bib13","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2019-00044","article-title":"Continuous versus bolus infusion of hypertonic saline in the treatment of symptomatic hyponatremia due to SIAD","author":"Garrahy","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2025.102055_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.akdh.2022.11.004","article-title":"Hyponatremia demystified: integrating physiology to shape clinical practice","volume":"30","author":"Workeneh","year":"2022","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.beem.2025.102055_bib15","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2025.102055_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5414\/CN110518","article-title":"Variations in daily urine solute output in patients with NDI, CDI, SIADH, and NSIAD: clinical implications","volume":"96","author":"Decaux","year":"2021","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.beem.2025.102055_bib17","series-title":"Physiologie des Menschen","year":"2011"},{"key":"10.1016\/j.beem.2025.102055_bib18","doi-asserted-by":"crossref","unstructured":"Heise T, Seman L, Macha S, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus. 2013;4:331-45.","DOI":"10.1007\/s13300-013-0030-2"},{"key":"10.1016\/j.beem.2025.102055_bib19","doi-asserted-by":"crossref","unstructured":"Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. 2013;2:152-61.","DOI":"10.1002\/cpdd.16"},{"key":"10.1016\/j.beem.2025.102055_bib20","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","author":"Jensen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2025.102055_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.beem.2025.102055_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2019.00271","article-title":"Empagliflozin contributes to polyuria via regulation of sodium transporters and water channels in diabetic rat kidneys","volume":"10","author":"Chung","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.beem.2025.102055_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2025.102055_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2025.102055_bib25","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00070.2022","article-title":"SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats","volume":"323","author":"Masuda","year":"2022","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.beem.2025.102055_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7815690","article-title":"Empagliflozin increases Short-Term urinary volume output in artificially induced syndrome of inappropriate antidiuresis","volume":"2017","author":"Refardt","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2025.102055_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.beem.2025.102055_bib28","unstructured":"Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study. \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03202667\u3009."},{"key":"10.1016\/j.beem.2025.102055_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2025.102055_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc23-1163","article-title":"Euglycemic ketoacidosis in two patients without diabetes after introduction of Sodium-Glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction","volume":"47","author":"Umapathysivam","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2025.102055_bib31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/dom.13900","article-title":"Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials","volume":"22","author":"Silverii","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2025.102055_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ki.2012.67","article-title":"New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism","volume":"81","author":"Bankir","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2025.102055_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000503773","article-title":"Urea for chronic hyponatremia","volume":"49","author":"Rondon-Berrios","year":"2020","journal-title":"Blood Purif"},{"key":"10.1016\/j.beem.2025.102055_bib34","first-page":"268","volume":"87","author":"Sterns","year":"2015","journal-title":"Urea hyponatremia?"},{"key":"10.1016\/j.beem.2025.102055_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ki.2015.138","article-title":"Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats","volume":"88","author":"Cil","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2025.102055_bib36","unstructured":"Nephcentric. ure-Na - Information for physicians. 2021."},{"key":"10.1016\/j.beem.2025.102055_bib37","unstructured":"KidneyAide L.L.C. UreaAide\u2122 Premium Urea Packets."},{"key":"10.1016\/j.beem.2025.102055_bib38","unstructured":"KidneyAide L.L.C. UreaTabs\u2122."},{"key":"10.1016\/j.beem.2025.102055_bib39","series-title":"Disorders of Fluid and Electrolyte Metabolism: Focus on Hyponatremia","first-page":"0","article-title":"Euvolemic hyponatremia secondary to the syndrome of inappropriate antidiuresis","author":"Verbalis","year":"2019"},{"key":"10.1016\/j.beem.2025.102055_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0002-9343(80)90506-9","article-title":"Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea","volume":"69","author":"Decaux","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2025.102055_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0006-8993(99)02259-3","article-title":"Azotemia (48h) decreases the risk of brain damage in rats after correction of chronic hyponatremia","volume":"852","author":"Soupart","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.beem.2025.102055_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/ki.2014.273","article-title":"Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline","volume":"87","author":"Gankam Kengne","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2025.102055_bib43","series-title":"Physiology and pathophysiology of water homeostasis","first-page":"8","author":"Rondon-Berrios","year":"2019"},{"key":"10.1016\/j.beem.2025.102055_bib44","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1210\/jc.2012-3225","article-title":"Severe hypernatremia from a Urea-Induced diuresis due to body protein wasting in an Insulin-Resistant type 2 diabetic patient","volume":"98","author":"Anderson","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.102055_bib45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ndt\/gfr428","article-title":"Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients","volume":"27","author":"Lindner","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.beem.2025.102055_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0026-0495(88)90028-5","article-title":"Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats","volume":"37","author":"Verbalis","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2025.102055_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/ejendo\/lvad108","article-title":"Effect of protein supplementation on plasma sodium levels in the syndrome of inappropriate antidiuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study","volume":"189","author":"Monnerat","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2025.102055_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMra071313","article-title":"Uremia","volume":"357","author":"Meyer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2025.102055_bib49","article-title":"Clinical factors associated with hyponatremia correction during treatment with oral urea","author":"Pelouto","year":"2024","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"10.1016\/j.beem.2025.102055_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s42000-023-00430-0","article-title":"Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature review","volume":"22","author":"Bioletto","year":"2023","journal-title":"Hormones"},{"key":"10.1016\/j.beem.2025.102055_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcsm.12048","article-title":"SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes","volume":"7","author":"Malmstrom","year":"2016","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"10.1016\/j.beem.2025.102055_bib52","doi-asserted-by":"crossref","unstructured":"Barsony J, Manigrasso MB, Xu Q, Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. 2013;35:271-88.","DOI":"10.1007\/s11357-011-9347-9"},{"issue":"1","key":"10.1016\/j.beem.2025.102055_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12877-020-01955-4","article-title":"Mild hyponatremia is associated with low skeletal muscle mass, physical function impairment, and depressive mood in the elderly","volume":"21","author":"Fujisawa","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.beem.2025.102055_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49054-8","article-title":"Impact of resolution of hyponatremia on neurocognitive and motor performance in geriatric patients","volume":"9","author":"Brinkkoetter","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2025.102055_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13022","article-title":"Impact of chronic hyponatremia on neurocognitive and neuromuscular function","volume":"48","author":"Refardt","year":"2018","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.beem.2025.102055_bib56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/eci.12597","article-title":"Impact of hyponatremia on nerve conduction and muscle strength","volume":"46","author":"Vandergheynst","year":"2016","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.beem.2025.102055_bib57","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1073\/pnas.92.4.1013","article-title":"Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane","volume":"92","author":"Nielsen","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.beem.2025.102055_bib58","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41581-021-00461-z","article-title":"The therapeutic potential of apelin in kidney disease","volume":"17","author":"Chapman","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.beem.2025.102055_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735515","article-title":"Apelin and vasopressin: the yin and yang of water balance","volume":"12","author":"Girault-Sotias","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2025.102055_bib60","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1046\/j.1471-4159.2001.00320.x","article-title":"Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain","volume":"77","author":"Reaux","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.beem.2025.102055_bib61","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1073\/pnas.0403518101","article-title":"Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release","volume":"101","author":"De Mota","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.beem.2025.102055_bib62","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1111\/bcp.15446","article-title":"Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function","volume":"88","author":"Nyimanu","year":"2022","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.beem.2025.102055_bib63","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ki.2008.199","article-title":"Effect of apelin on glomerular hemodynamic function in the rat kidney","volume":"74","author":"Hus-Citharel","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2025.102055_bib64","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/en.2014-1257","article-title":"Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct","volume":"155","author":"Hus-Citharel","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2025.102055_bib65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.33594\/000000165","article-title":"Apelin-13 regulates Vasopressin-Induced Aquaporin-2 expression and trafficking in kidney collecting duct cells","volume":"53","author":"Boulkeroua","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.beem.2025.102055_bib66","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.1038\/s41467-024-52447-7","article-title":"Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study","volume":"15","author":"Chapman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2025.102055_bib67","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacc.2008.06.013","article-title":"Vascular effects of apelin in vivo in man","volume":"52","author":"Japp","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beem.2025.102055_bib68","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/cbic.201600244","article-title":"The metalloprotease neprilysin degrades and inactivates apelin peptides","volume":"17","author":"McKinnie","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.beem.2025.102055_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20560-y","article-title":"A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia","volume":"12","author":"Flahault","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2025.102055_bib70","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae106","article-title":"Apelin and copeptin levels in patients with chronic SIAD treated with empagliflozin","volume":"8","author":"Monnerat","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2025.102055_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177302","article-title":"Advances in the therapeutic potentials of ligands of the apelin receptor APJ","volume":"991","author":"Wagenaar","year":"2025","journal-title":"Eur J Pharm"},{"key":"10.1016\/j.beem.2025.102055_bib72","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bph.14603","article-title":"A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension","volume":"176","author":"Yang","year":"2019","journal-title":"Br J Pharm"},{"key":"10.1016\/j.beem.2025.102055_bib73","article-title":"The g protein biased small molecule apelin agonist CMF-019 is disease modifying in endothelial cell apoptosis in vitro and induces vasodilatation without desensitisation in vivo","volume":"11","author":"Read","year":"2020","journal-title":"Front Pharm"},{"key":"10.1016\/j.beem.2025.102055_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/FJC.0000000000001671","article-title":"Activation of APJ receptors by CMF-019, but not apelin, causes Endothelium-Dependent relaxation of spontaneously hypertensive rat coronary arteries","volume":"85","author":"Anto","year":"2025","journal-title":"J Cardiovasc Pharm"},{"key":"10.1016\/j.beem.2025.102055_bib75","article-title":"A First-in-Human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients","author":"Winkle","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.beem.2025.102055_bib76","unstructured":"Novartis P. A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients. Clinical Trial Results Report. 2019."},{"key":"10.1016\/j.beem.2025.102055_bib77","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.advms.2020.02.002","article-title":"Role of Apelin\/APJ axis in cancer development and progression","volume":"65","author":"Masoumi","year":"2020","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.beem.2025.102055_bib78","article-title":"The role of apelin in the retina of diabetic rats","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2025.102055_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112855","article-title":"Modern trends in diuretics development","volume":"208","author":"Titko","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.beem.2025.102055_bib80","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/biomedicines11020607","article-title":"Urea transporter inhibitor 25a reduces ascites in cirrhotic rats","volume":"11","author":"Ying","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.beem.2025.102055_bib81","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2025.102055_bib82","doi-asserted-by":"crossref","first-page":"9317","DOI":"10.1073\/pnas.97.16.9317","article-title":"Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation","volume":"97","author":"Bethin","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.beem.2025.102055_bib83","first-page":"934","article-title":"Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion","volume":"79","author":"Mastorakos","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.102055_bib84","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.90489.2008","article-title":"Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats","volume":"296","author":"Palin","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.beem.2025.102055_bib85","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0171","article-title":"Inverse relationship between IL-6 and sodium levels in patients with COVID-19 and other respiratory tract infections: data from the COVIVA study","volume":"11","author":"Atila","year":"2022","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2025.102055_bib86","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40618-020-01301-w","article-title":"Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?","volume":"43","author":"Berni","year":"2020","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.beem.2025.102055_bib87","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4174","article-title":"SIADH in systemic JIA resolving after treatment with an IL-6 inhibitor","volume":"141","author":"Hodax","year":"2018","journal-title":"Pediatrics"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X25000880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:23:55Z","timestamp":1787153035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X25000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1521690X25000880"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2025.102055","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potential treatment options for syndrome of inappropriate antidiuresis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2025.102055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102055"}}